{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:07:04Z","timestamp":1794344824067,"version":"4.9.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-025-03823-6","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T14:10:23Z","timestamp":1752934223000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effect of triple therapy on mortality and cardiovascular risk in patients with moderate to severe COPD: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Yubing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"issue":"9867","key":"3823_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9867):2095\u2013128.","journal-title":"Lancet"},{"key":"3823_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/resp.12660","volume":"21","author":"JL L\u00f3pez-Campos","year":"2016","unstructured":"L\u00f3pez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21:14\u201323.","journal-title":"Respirology"},{"issue":"11","key":"3823_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/thx.2005.040527","volume":"60","author":"JJ Soler-Catalu\u00f1a","year":"2005","unstructured":"Soler-Catalu\u00f1a JJ, Mart\u00ednez-Garc\u00eda MA, Rom\u00e1n S\u00e1nchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925\u201331.","journal-title":"Thorax"},{"issue":"5","key":"3823_CR4","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1164\/ajrccm.163.5.2101039","volume":"163","author":"RA Pauwels","year":"2001","unstructured":"Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI\/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256\u201376.","journal-title":"Am J Respir Crit Care Med"},{"key":"3823_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2147\/COPD.S233734","volume":"15","author":"CC Lai","year":"2020","unstructured":"Lai CC, Chen CH, Lin CYH, Wang CY, Wang YH. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials [published correction appears in. Int J Chron Obstruct Pulmon Dis. 2020;15:155\u20136.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"3823_CR6","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1007\/s12325-020-01311-3","volume":"37","author":"GT Ferguson","year":"2020","unstructured":"Ferguson GT, Darken P, Ballal S, et al. Efficacy of budesonide\/glycopyrronium\/formoterol fumarate metered dose inhaler (BGF MDI) versus other inhaled Corticosteroid\/Long-Acting muscarinic Antagonist\/Long-Acting \u03b22-Agonist (ICS\/LAMA\/LABA) triple combinations in COPD: A systematic literature review and network Meta-analysis. Adv Ther. 2020;37(6):2956\u201375.","journal-title":"Adv Ther"},{"issue":"6","key":"3823_CR7","first-page":"592","volume":"379","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Criner GJ, Lomas DA. Single-Inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;379(6):592\u20133.","journal-title":"N Engl J Med"},{"issue":"1","key":"3823_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020;383(1):35\u201348.","journal-title":"N Engl J Med"},{"issue":"11","key":"3823_CR9","doi-asserted-by":"publisher","first-page":"e1002958","DOI":"10.1371\/journal.pmed.1002958","volume":"16","author":"HW Lee","year":"2019","unstructured":"Lee HW, Park J, Jo J, Jang EJ, Lee CH. Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: systematic review and bayesian network meta-analysis. PLoS Med. 2019;16(11):e1002958.","journal-title":"PLoS Med"},{"issue":"3","key":"3823_CR10","first-page":"CD010115","volume":"2014","author":"KM Kew","year":"2014","unstructured":"Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;2014(3):CD010115.","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"3823_CR11","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamainternmed.2013.1016","volume":"173","author":"A Gershon","year":"2013","unstructured":"Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173(13):1175\u201385.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"3823_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12931-021-01777-x","volume":"22","author":"A Koarai","year":"2021","unstructured":"Koarai A, Yamada M, Ichikawa T, Fujino N, Kawayama T, Sugiura H. Triple versus LAMA\/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. Respir Res. 2021;22(1):183.","journal-title":"Respir Res"},{"issue":"1","key":"3823_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12931-021-01794-w","volume":"22","author":"H Long","year":"2021","unstructured":"Long H, Xu H, Janssens JP, Guo Y. Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials. Respir Res. 2021;22(1):209.","journal-title":"Respir Res"},{"key":"3823_CR14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3389\/fphar.2019.00975","volume":"10","author":"C Bousquet","year":"2019","unstructured":"Bousquet C, Souvignet J, Sadou \u00c9, Jaulent MC, Declerck G. Ontological and Non-Ontological resources for associating medical dictionary for regulatory activities terms to SNOMED clinical terms with semantic properties. Front Pharmacol. 2019;10:975.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3823_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1183\/13993003.02165-2015","volume":"48","author":"SJ Pascoe","year":"2016","unstructured":"Pascoe SJ, Lipson DA, Locantore N, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48(2):320\u201330.","journal-title":"Eur Respir J"},{"issue":"8","key":"3823_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.7326\/0003-4819-146-8-200704170-00152","volume":"146","author":"SD Aaron","year":"2007","unstructured":"Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545\u201355.","journal-title":"Ann Intern Med"},{"issue":"4","key":"3823_CR17","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s12325-020-01266-5","volume":"37","author":"C Wang","year":"2020","unstructured":"Wang C, Yang T, Kang J, et al. Efficacy and safety of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler in Chinese patients with COPD: A subgroup analysis of KRONOS. Adv Ther. 2020;37(4):1591\u2013607.","journal-title":"Adv Ther"},{"issue":"1","key":"3823_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12931-020-01398-w","volume":"21","author":"NC Day","year":"2020","unstructured":"Day NC, Kumar S, Criner G, et al. Single-inhaler triple therapy fluticasone furoate\/umeclidinium\/vilanterol versus fluticasone furoate\/vilanterol and umeclidinium\/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial. Respir Res. 2020;21(1):139.","journal-title":"Respir Res"},{"issue":"10","key":"3823_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind,parallel-group,multicentre,phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747\u201358.","journal-title":"Lancet Respir Med"},{"key":"3823_CR20","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.2147\/COPD.S220861","volume":"14","author":"M Ichinose","year":"2019","unstructured":"Ichinose M, Fukushima Y, Inoue Y, et al. Long-Term safety and efficacy of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler formulated using Co-Suspension delivery technology in Japanese patients with COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:2993\u20133002.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"3823_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12931-021-01683-2","volume":"22","author":"J Zheng","year":"2021","unstructured":"Zheng J, Baldi S, Zhao L, et al. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in Eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial. Respir Res. 2021;22(1):90.","journal-title":"Respir Res"},{"issue":"1","key":"3823_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12931-019-1126-7","volume":"20","author":"EM Kerwin","year":"2019","unstructured":"Kerwin EM, Ferguson GT,Mo M, Dorinsky P. Bone and ocular safety of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study. Respir Res. 2019;20(1):167.","journal-title":"Respir Res"},{"issue":"5","key":"3823_CR23","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","volume":"203","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced All-Cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, Double-Blind, multicenter, Parallel-Group study. Am J Respir Crit Care Med. 2021;203(5):553\u201364.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10125","key":"3823_CR24","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S0140-6736(18)30206-X","volume":"391","author":"A Papi","year":"2018","unstructured":"Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1022.","journal-title":"Lancet"},{"issue":"9","key":"3823_CR25","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.rmed.2015.06.006","volume":"109","author":"TM Siler","year":"2015","unstructured":"Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A. Efficacy and safety of Umeclidinium added to fluticasone furoate\/vilanterol in chronic obstructive pulmonary disease: results of two randomized studies. Respir Med. 2015;109(9):1155\u201363.","journal-title":"Respir Med"},{"issue":"10048","key":"3823_CR26","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","volume":"388","author":"D Singh","year":"2016","unstructured":"Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963\u201373.","journal-title":"Lancet"},{"key":"3823_CR27","doi-asserted-by":"publisher","first-page":"16031","DOI":"10.1038\/npjpcrm.2016.31","volume":"26","author":"AR Sousa","year":"2016","unstructured":"Sousa AR, Riley JH, Church A, Zhu CQ, Punekar YS, Fahy WA. The effect of Umeclidinium added to inhaled corticosteroid\/long-acting \u03b22-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study. NPJ Prim Care Respir Med. 2016;26:16031.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"2","key":"3823_CR28","first-page":"173","volume":"12","author":"CC Lai","year":"2022","unstructured":"Lai CC, Chen CH, Chen KH, et al. The impact of 52-Week single inhaler device triple therapy versus dual therapy on the mortality of COPD patients: A systematic review and Meta-Analysis of randomized controlled trials. Life (Basel). 2022;12(2):173.","journal-title":"Life (Basel)"},{"issue":"18","key":"3823_CR29","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671\u201380.","journal-title":"N Engl J Med"},{"issue":"7","key":"3823_CR30","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/resp.12780","volume":"21","author":"FW Ko","year":"2016","unstructured":"Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD. Respirology. 2016;21(7):1152\u201365.","journal-title":"Respirology"},{"issue":"5","key":"3823_CR31","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1378\/chest.09-2029","volume":"137","author":"GC Donaldson","year":"2010","unstructured":"Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091\u20137.","journal-title":"Chest"},{"issue":"1","key":"3823_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","volume":"198","author":"KM Kunisaki","year":"2018","unstructured":"Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"3823_CR33","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.2147\/COPD.S200846","volume":"14","author":"CC Lai","year":"2019","unstructured":"Lai CC, Chen CH, Lin CYH, Wang CY, Wang YH. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. Int J Chron Obstruct Pulmon Dis. 2019;14:1539\u201348.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"3823_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/17476348.2020.1816830","volume":"15","author":"L Calzetta","year":"2021","unstructured":"Calzetta L, Ritondo BL, de Marco P, Cazzola M, Rogliani P. Evaluating triple ICS\/LABA\/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Rev Respir Med. 2021;15(1):143\u201352.","journal-title":"Expert Rev Respir Med"},{"issue":"7","key":"3823_CR35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/crj.13026","volume":"13","author":"Y Zayed","year":"2019","unstructured":"Zayed Y, Barbarawi M, Kheiri B, et al. Triple versus dual inhaler therapy in moderate-to-severe COPD: A systematic review and meta-analysis of randomized controlled trials. Clin Respir J. 2019;13(7):413\u201328.","journal-title":"Clin Respir J"},{"issue":"1","key":"3823_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1164\/rccm.201610-2086OC","volume":"197","author":"PMA Calverley","year":"2018","unstructured":"Calverley PMA, Anderson JA, Brook RD, et al. Fluticasone furoate, vilanterol, and lung function decline in patients with moderate chronic obstructive pulmonary disease and heightened cardiovascular risk. Am J Respir Crit Care Med. 2018;197(1):47\u201355.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"3823_CR37","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914.","journal-title":"N Engl J Med"},{"key":"3823_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.rmed.2018.08.013","volume":"143","author":"P Pirina","year":"2018","unstructured":"Pirina P, Foschino Barbaro MP, Paleari D, Spanevello A. Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta2-agonists formulations in chronic obstructive pulmonary disease. Respir Med. 2018;143:74\u201381. https:\/\/doi.org\/10.1016\/j.rmed.2018.08.013.","journal-title":"Respir Med"},{"issue":"6","key":"3823_CR39","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1183\/09031936.00079512","volume":"41","author":"J Hurdman","year":"2013","unstructured":"Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. 2013;41(6):1292\u2013301.","journal-title":"Eur Respir J"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03823-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-025-03823-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-025-03823-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:17:26Z","timestamp":1757258246000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-025-03823-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3823"],"URL":"https:\/\/doi.org\/10.1186\/s12890-025-03823-6","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"345"}}